Promed P.Lach R.Glowacki Sp. j.

Promed P.Lach R.Glowacki Sp. j. is conducting studies that target heart failure and related kidney impairment, aiming to test novel drug combinations for reducing cardiovascular death and hospitalizations.

• Evaluation of a dual therapy versus standard SGLT2 inhibitor in chronic heart failure
• Assessment of fluid retention and blood pressure effects of combined endothelin and SGLT2 inhibition
• Long‑term safety monitoring of cardiovascular outcomes in patients with comorbid renal disease

The trials involve 23 investigators and contribute to the 41 active studies at the Kraków site.

Research at the center focuses on chronic obstructive pulmonary disease and severe asthma, testing new biologics and inhaled combinations to lessen exacerbations and improve lung function.

• Comparison of a novel anti‑IL‑33 antibody with placebo in uncontrolled asthma
• Triple inhaler therapy versus dual bronchodilator regimen for COPD outcomes
• Evaluation of a bacterial lysate for reducing recurrent respiratory infections in young children

These projects aim to expand therapeutic options for patients with persistent respiratory symptoms.

The site is active in trials for inflammatory bowel conditions such as Crohn’s disease and ulcerative colitis, investigating agents that promote remission and heal intestinal lining.

• Induction of clinical remission with a new oral small‑molecule in moderate‑to‑severe Crohn’s disease
• Combination of two biologics versus monotherapy for ulcerative colitis
• Oral mesalazine formulation for mild‑to‑moderate ulcerative colitis induction

The studies seek to improve quality of life for patients with chronic gastrointestinal inflammation.

Investigations include plaque psoriasis and various forms of lupus, with the goal of confirming efficacy of emerging monoclonal antibodies and small molecules.

• Assessment of a novel JAK inhibitor in moderate‑to‑severe plaque psoriasis
• Evaluation of an anti‑IL‑23 agent for skin disease activity in cutaneous lupus
• Long‑term safety of a new IL‑17 blocker in chronic plaque psoriasis

Outcomes will help define next‑generation treatments for patients with refractory skin disorders.

Promed’s trials address autoimmune conditions such as Sjögren’s syndrome and systemic lupus erythematosus, focusing on therapies that modulate immune pathways.

• Effect of a novel BTK inhibitor on systemic manifestations of Sjögren’s syndrome
• Safety and efficacy of a dual‑target antibody in subacute cutaneous lupus erythematosus
• Investigation of a complement inhibitor for preserving kidney function in IgA nephropathy

These studies aim to reduce disease activity and organ damage in autoimmune patients.

The Kraków facility conducts research on IgA nephropathy and chronic kidney disease, testing agents that may slow disease progression and protect renal function.

• Evaluation of a complement C5 inhibitor on proteinuria reduction
• Comparison of a combined endothelin/SGLT2 blocker versus standard therapy in CKD
• Long‑term tolerability of a novel immunomodulator in patients with IgA nephropathy

Results could influence future management of renal impairment associated with systemic diseases.

Clinical work includes studies on migraine, aiming to evaluate acute and preventive treatments that reduce headache frequency and severity.

• Single‑dose monoclonal antibody for acute episodic migraine relief
• Assessment of a novel CGRP pathway inhibitor for chronic migraine prevention
• Safety monitoring of long‑term use of migraine‑targeted biologics

The trials support the development of better therapeutic options for patients suffering from disabling headaches.